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OBJECTIVES We examined the diagnostic performance of serum myoglobin, creatine-kinase-MB (CK-
MB) and cardiac Troponin-I (cTnI) for predicting the infarct-related artery (IRA) patency in
patients receiving TNK-tissue plasminogen activator (TNK-tPA) therapy for acute myocar-
dial infarction (AMI) in the Thrombolysis in Myocardial Infarction (TIMI) 10B trial.
BACKGROUND A reliable noninvasive serum marker of IRA patency is desired to permit early identification
of patients with a patent IRA after thrombolysis.
METHODS We measured myoglobin, CK-MB and cTnI concentrations in sera obtained just before
thrombolysis (T0) and 60 min later (T60) in 442 patients given TNK-tPA and who
underwent coronary angiography at 60 min.
RESULTS Angiography at 60 min showed a patent IRA (TIMI flow grade 2, 3) in 344 and occluded
IRA (TIMI flow grade 0, 1) in 98 patients. The median serum T60 concentration, the ratio
of the T60 and T0 serum concentration (60-min ratio) and the slope of increase over 60 min
for each serum marker were significantly higher in patients with patent arteries compared with
patients with occluded arteries. The area under the receiver-operating characteristic (ROC) curve
for diagnosis of occlusion was 0.71, 0.70 and 0.71 for the 60-min ratio of myoglobin, cTnI and
CKMB, respectively. The 60-min ratios of $4.0 for myoglobin, $3.3 for CK-MB and $2.0 for
cTnI yielded a probability of patency of 90%, 88% and 87%, respectively.
CONCLUSIONS The diagnostic performance of serum myoglobin, CK-MB and cardiac Tropinin-I (cTnI)
60-min ratios was similar. The probability of a patent IRA was very high (90%) in patients
with 60-min myoglobin ratio $4.0, and early invasive interventions to establish IRA patency
may not be necessary in this group. Serum marker determinations at baseline and 60-min
after thrombolysis may permit rapid triage of patients receiving thrombolytic therapy by
ruling out IRA occlusion. (J Am Coll Cardiol 1999;34:739–47) © 1999 by the American
College of Cardiology
Early thrombolysis in patients with acute myocardial infarc-
tion (AMI) has a strong beneficial influence on short- and
long-term outcome (1,2). The therapeutic goal of infarct-
related artery (IRA) patency may be achieved with novel
thrombolytic agents or percutaneous coronary interventions
(3–6). The availability of a reliable marker of IRA patency
status may permit early identification of patients with patent
IRA, for whom repeat thrombolysis or rescue percutaneous
transluminal coronary angioplasty (PTCA) may not be
necessary. Although coronary angiography has been consid-
ered the gold standard for this purpose (4,5), it is costly and
often unavailable for routine care of most patients. Because
the currently used noninvasive clinical and electrocardio-
graphic indexes of IRA patency status are not sufficiently
sensitive nor specific (7,8), several serum cardiac markers
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have been investigated and proposed as alternatives. The
serum markers that have been investigated include creatine
kinase-MB (CK-MB) (9–12), total creatine kinase (CK)
(10,13), myoglobin (12,14–16), cardiac Troponin-T (17–
20), CK isoforms (21,22), cardiac Troponin-I (cTnI)
(12,23) and combinations of the above (12,18,24,25).
The current study was undertaken to examine the diag-
nostic performance of serum myoglobin, CK-MB and cTnI
obtained immediately before, and within 60 min of initia-
tion of thrombolysis, for predicting the IRA patency in
patients receiving TNK-tissue plasminogen activator
(TNK-tPA) therapy in the Thrombolysis in Myocardial
Infarction (TIMI) 10B trial.
METHODS
TIMI 10B trial. The TIMI 10B trial, a phase-II, dose-
ranging trial was conducted in the U.S. and Europe between
March 1996 and March 2, 1997. It evaluated the new
thrombolytic agent, TNK-tPA, in patients with AMI (26).
The study patients were between the ages of 19 and 80
years, had episodes of ischemic discomfort lasting
$30 min and presented within 12 h from symptom onset,
associated with ST segment elevation $0.1 mV in two or
more contiguous electrocardiogram (ECG) leads. Major
exclusion criteria included prior stroke or transient
ischemic attack, a reliably obtained blood pressure
.180/110 mm Hg, significant bleeding within six months
and other contraindications to thrombolysis.
Eligible patients were randomized to receive either a
single bolus of 30, 40 or 50 mg TNK-tPA (Genentech, Inc.,
South San Francisco, California) or front-loaded (t-PA).
All patients received aspirin and intravenous heparin. Pa-
tients underwent coronary angiography at 90 min, and 60
and 75 min when feasible. All angiograms were analyzed at
the Angiographic Core Laboratory (VA Medical Center,
West Roxbury, Massachusetts), which was blinded to dose
assignment. Thrombolysis in myocardial infarction flow
grade was analyzed according to prespecified definitions
(27).
The TIMI 10B study protocol was reviewed and ap-
proved by each hospital’s Institutional Review Board, and
written informed consent was obtained from each patient
before enrollment.
Study population. In an ancillary study reported here,
blood specimens for serum marker analyses were collected in
826 patients. The patients with no available information
regarding the time interval between the onset of chest pain
and the initiation of thrombolysis (n 5 31) were excluded.
Only patients for whom the 60-min angiogram was avail-
able (n 5 442) were included in the statistical analyses.
Separate statistical analyses were performed on the subset of
patients that received thrombolytic treatment within 6 h
from the onset of ischemic discomfort (n 5 378).
Serum marker analyses. Serum specimens were obtained
by centrifugation at each site, and were stored locally at
220°C. They were then mailed on dry ice to the Covance
Core Laboratory (Indianapolis, Indiana), where they were
stored at 270°C. The specimens were shipped to the
Cardiac Serum Marker Core Laboratory, at the Clinical
Chemistry Laboratory of the Brigham and Women’s Hos-
pital (Boston), and stored at 220°C until analysis. The
cardiac marker proteins remain stable when handled in this
manner (data on file; Dade Behring Inc., Newark, Dela-
ware). In the current study, the specimens were thawed and
analyzed in batches by individuals blinded to the clinical
data. Cardiac Troponin I, CK-MB and myoglobin were
measured by the Stratus fluorometric enzyme immunoassays
(Dade Behring). The analysis time is 15 min for each
marker. The cTnI assay uses two cTnI-specific monoclonal
antibodies that recognize two different cTnI epitopes
(28,29). This assay shows no cross-reactivity with human
skeletal muscle TnI (28,30). The myoglobin sandwich
immunoassay uses two myoglobin-specific monoclonal an-
tibodies (31,32). Creatine-kinase-MB concentrations were
measured with an immunoassay based on a monoclonal
antibody specific for the CK-MB isoenzyme (33,34). All
CK-MB and cTnI results below the lower detection limit of
their respective assays (i.e., ,0.4 ng/ml for both markers)
were collectively expressed as 0.4 ng/ml.
The imprecision of the cardiac marker assays, expressed
as between-run coefficient of variation (%CV), was assessed
over a period of 15 months, using the quality control
materials provided by the manufacturer (Dade Behring).
The imprecision of the myoglobin assay for concentrations
of 47.3, 223.1 and 442.3 ng/ml was 8.6%, 6.2% and 6.1%,
respectively. The between-run CV of the CK-MB assay for
concentrations of 5.6, 32.1 and 81.2 ng/ml was 8.2%, 7.8%
and 6.2%, respectively. The imprecision of the cTnI assays
for concentrations of 1.1, 4.6, 18.5 and 33.6 ng/ml was
7.8%, 6.6%, 7.5% and 5.6%, respectively.
Study end points. End points in this substudy included the
diagnostic characteristics for the following measurements
and indexes for each marker: value obtained 60 min after
initiation of treatment (T60); ratio of the 60-min (T60)
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
AUC 5 area under the receiver-operating
characteristic curve
CK-MB 5 creatine-kinase-MB
cTnI 5 cardiac Troponin-I
ECG 5 electrocardiogram
IRA 5 infarct-related artery
PTCA 5 percutaneous transluminal coronary
angioplasty
ROC 5 receiver-operating characteristics
TIMI 5 Thrombolysis in Myocardial Infarction
TNK-tPA 5 TNK-tissue plasminogen activator
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over baseline (T0) value (T60/T0); 60-min slope, calculated
by dividing the difference of the values at initiation of
therapy and 60 min thereafter by 60 ([T60-T0]/60), and
expressed in nanograms per milliliter/min. The TIMI flow
grade at 60 min was used as a gold standard (12). A TIMI
flow grade $2 was considered a patent IRA (n 5 344) and
a TIMI flow grade #1 was considered an occluded IRA
(n 5 98).
Statistical analyses. Baseline patient characteristics and all
other results are expressed as medians 6 interquartile
ranges. Statistical comparison of the baseline characteristics
between patients with patent and occluded IRAs were
performed via the chi-square test for categorical variables
and the Mann-Whitney test for continuous variables. The
significance of the differences between the marker values or
indexes obtained in the two groups of patients was deter-
mined by the Mann-Whitney test. Receiver-operating char-
acteristic (ROC) curves were constructed for the T0, T60,
60-min ratio and 60-min slope of each marker studied, by
plotting sensitivity against (12specificity) (35). Statistical
differences associated with a p , 0.05 were considered
significant.
RESULTS
Patient characteristics. The baseline demographic and
clinical characteristics of the 442 patients included in this
analysis are summarized in Table 1. There were 333 men
and 109 women with a median age of 60 years. The time
interval from the onset of chest pain to start of thrombolytic
therapy was 2.9 h (2.0 to 4.2 h). In 344 (78%) patients,
angiography at 60 min revealed TIMI flow grade 2 or 3. In
the remaining 98 (22%) patients, the TIMI flow grade was
0 or 1. The time interval from the onset of chest pain to start
of thrombolytic therapy was shorter (p , 0.001) in patients
with patent IRA (Table 1).
The median age among the subset of patients that
received thrombolysis within 6 h from pain onset was 59
years. The time interval from the pain onset to start of
thrombolytic therapy in this subgroup was 2.7 h (1.9 to
3.5 h). Angiography at 60 min revealed TIMI flow grade 2
Table 1. Baseline Characteristics for the Study Population
All Patients
Study Population
(n 5 422)
Patency TIMI
Flow 2 or 3
(n 5 344)
Persistent Occlusion
TIMI Flow 0 or 1
(n 5 98) p Value
Age (yr) 60 (51–69) 60 (51–69) 60 (50–69) NS
Male gender (%) 75.4 75.1 75.0 NS
Time from pain onset
to treatment (h)
2.9 (2.0–4.2) 2.7 (2.0–4.0) 3.5 (2.3–5.3) , 0.001
Infarct-related artery (%) LAD 38 40 31 NS
LCx 11 10 16
RCA 51 50 53
TIMI flow grade at
60 min (%)
0 19
1 3
2 29
3 49
Time Since Pain <6 h
Study Population
(n 5 378)
Patency TIMI
Flow 2 or 3
(n 5 299)
Persistent Occlusion
TIMI Flow 0 or 1
(n 5 79) p Value
Age (yr) 59 (50–69) 59 (50–69) 59 (50–71) NS
Male gender (%) 78.1 81.0 69.6 NS
Time from pain onset
to treatment (h)
2.7 (1.9–3.5) 2.5 (1.9–3.3) 3.0 (2.1–4.0) , 0.004
Infarct-related artery (%) LAD 34 36 26 NS
LCx 14 13 18
RCA 52 51 56
TIMI flow grade at
60 min (%)
0 18
1 3
2 28
3 51
Results are expressed as medians (25th and 75th) percentiles. LAD 5 left anterior descending artery; LCx 5 left circumflex
artery; RCA 5 right coronary artery; TIMI 5 Thrombolysis in Myocardial Infarction.
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or 3 in 299 (79%) and TIMI flow grade 0 or 1 in 79 (21%)
of these patients. Similar to the entire patient population,
the time interval from pain onset to start of thrombolytic
therapy was shorter (p , 0.004) in patients with a patent
IRA.
Changes in serum marker levels in thrombolysis. Table 2
summarizes the changes in serum levels of myoglobin,
CK-MB and cTnI before and 60 min after initiation of
thrombolytic therapy. In the overall study population of 442
patients, the baseline (T0) concentrations for all three serum
markers were significantly higher in the patients with an
occluded IRA (p , 0.001, p , 0.0001 and p , 0.004 for
myoglobin, CK-MB and cTnI, respectively), possibly due to
the larger extent of myocardial injury in this group. How-
ever, this trend was reversed 60 min after thrombolysis, as
evidenced by the significantly higher T60 concentrations of
myoglobin (p , 0.0001) and cTnI (p , 0.006) and
borderline significantly higher CK-MB (p , 0.06) in the
patients with a patent IRA.
Median ratios of the serum concentration 60 min after
the start of thrombolysis and at baseline (60-min ratio) were
consistently higher in patients in whom a patent IRA was
found, compared with those of patients with an occluded
IRA. The differences reached high statistical significance for
all three serum markers (p , 0.0001). Similarly, the
medians of the slopes of increase for each serum marker
within the first 60 min (60-min slope) were significantly
higher in patients with a patent IRA (p , 0.0001). These
observations were sustained in the subgroup of 378 patients
who received thrombolysis within 6 h of ischemic discom-
fort.
Table 2. Serum Cardiac Marker Concentrations and Indexes in the Study Group
All Patients
Patency
TIMI Grades 2–3
(n 5 344)
Persistent Occlusion
TIMI Grades 0–1
(n 5 98) p Value
Myoglobin
T0 98.5 (47, 251) 172 (69, 462) , 0.001
T60 1131 (376, 2589) 510 (174, 978) , 0.0001
60-min ratio 7.3 (1.8, 26.3) 1.9 (1.2, 3.7) , 0.0001
60-min slope* 14.2 (2.3, 38.9) 2.7 (0.8, 7.1) , 0.0001
CK-MB mass
T0 2.0 (0.4, 5.6) 4.1 (1.3, 13.6) , 0.0001
T60 19.0 (6.3, 43.8) 9.7 (5.0, 34.3) , 0.06
60-min ratio 6.1 (2.0, 21.0) 2.1 (1.3, 3.7) , 0.0001
60-min slope* 0.22 (0.05, 0.59) 0.09 (0.02, 0.22) , 0.0001
cTnI
T0 0.4 (0.4, 0.8) 0.4 (0.4, 2.8) , 0.004
T60 2.8 (0.4, 11.5) 1.1 (0.4, 5.9) , 0.006
60-min ratio 3.3 (1.0, 13.0) 1.0 (1.0, 2.2) , 0.0001
60-min slope* 0.03 (0.0, 0.16) 0.0 (0.0, 0.03) , 0.0001
Time Since Pain <6 h
Myoglobin
T0 (ng/ml) 89 (46, 217) 140 (66, 275) , 0.02
T60 (ng/ml) 1279 (389, 2820) 474 (169, 950) , 0.0001
60-min ratio 9.0 (2.1, 30.6) 2.2 (1.5, 5.1) , 0.0001
60-min slope* 16.7 (3.0, 42.5) 2.9 (0.8, 8.6) , 0.0001
CK-MB mass
T0 (ng/ml) 1.4 (0.4, 4.5) 2.7 (1.1, 6.7) , 0.004
T60 (ng/ml) 18.5 (6.1, 43.4) 7.9 (4.8, 22.2) , 0.002
60-min ratio 7.3 (2.3, 24.0) 2.4 (1.6, 4.0) , 0.001
60-min slope* 0.22 (0.06, 0.61) 0.09 (0.03, 0.18) , 0.001
cTnI
T0 0.4 (0.4, 0.5) 0.4 (0.4, 1.2) NS
T60 2.7 (0.4, 11.4) 0.7 (0.4, 2.4) , 0.0002
60-min ratio 3.7 (1.0, 14.5) 1.0 (1.0, 2.2) , 0.0001
60-min slope* 0.03 (0.0, 0.16) 0.0 (0.0, 0.02) , 0.0001
Results displayed in median and 25th and 75th percentiles.
*60-min slope expressed as ng/ml/min.
CK-MB 5 creatine-kinase-MB; cTnI 5 cardiac Troponin-I; TIMI 5 Thrombolysis in Myocardial Infarction.
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Diagnostic performance of serum markers in thrombol-
ysis. Because the myoglobin, CK-MB and cTnI assays
produce results along a continuum, an ROC analysis was
employed to compare their diagnostic value for noninvasive
assessment of a patent IRA 60 min after initiation of
thrombolysis. Comparison of the area under the ROC curve
(AUC) for the 60-minute ratios in the overall patient
population (Fig. 1, middle), showed equivalent performance
between myoglobin (AUC 5 0.71), cTnI (AUC 5 0.71)
and CK-MB (AUC 5 0.70). The difference in the AUC
between the 60-min ratios for the three markers was not
statistically significant. The peformance of the 60-min
ratios for all three markers in the subset of patients that were
treated within 6 h from onset of ischemic discomfort was
identical to the overall patient population. Analysis of the
T60 concentration (Fig. 1, top) and the 60-min slopes (Fig.
1, bottom) revealed suboptimal AUC for all three markers,
with exception of the 60-min myoglobin slope (AUC 5
0.70).
The data obtained from the ROC analyses were applied
to determine the cut-points for the 60-min ratios of all three
serum markers, above which the probability of a patent IRA
could be predicted with a high degree of diagnostic accu-
racy. The performance of all three markers was very similar
in the overall patient population, as well as in patients
treated within 6 h from onset of ischemic discomfort (Table
3). In the overall patient population, the 60-min myoglobin
ratio of ,4.0 yielded slightly better sensitivity (74%) and
specificity (64%) for occlusion of the IRA than the other
two serum markers. When the 60-min myoglobin ratio was
$4.0, the probability of a patent IRA was 90%, and only 23
out of 229 (10%) patients with values above these levels
showed documented occlusion of the IRA at angiography
performed 60 min after thrombolysis. The probability of
patent IRA increased further with increasing myoglobin
60-min ratios (Fig. 2). The probability of occlusion was low
(37%), even with 60-min myoglobin ratios of ,4.0 (Tables
3 and 4). The predictive value for occlusion increased by
only 4% when the combination of myoglobin 60-min ratios
of ,4.0 for myoglobin, ,2.0 for cTnI and ,3.3 for
CK-MB was considered evidence of occlusion.
Further analyses were performed to determine whether
the performance of the 60-min ratios for all three markers
could be improved by segregating the patients based on
whether the initial serum myoglobin or cTnI values were
higher or lower than their respective diagnostic cutoffs for
AMI (.110 and .0.4 ng/ml, respectively). Some improve-
ment in clinical performance was observed for the 60-min
Figure 1. ROC curves of the 60-min value (top), 60-min ratio (middle) and 60-min slope (bottom) of myoglobin, CK-MB and cardiac
Troponin-I (cTnI), for noninvasive prediction of occlusion after thrombolysis.
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cTnI ratio using the diagnostic cutpoint of 2.5, in the
subgroup of patients with elevated baseline myoglobin
(AUC 5 0.77) or cTnI values (AUC 5 0.72). However, the
probability of occlusion when the cTnI 60-min ratio was
,2.5 ng/ml was only 46% in this subgroup. This is only
marginally higher than the probability of occlusion of 37%
yielded by the 60-min myoglobin ratios of ,4.0 in the
entire patient population.
None of the markers was sufficiently accurate to differ-
entiate patients with TIMI flow grade 3 from TIMI flow
grade #2 (e.g., AUC 5 0.64 for myoglobin 60-min ratio).
The probability of TIMI flow grade of 3 when the 60-min
myoglobin ratio was $4.0 was only 59%.
DISCUSSION
The aim of the current study was to assess the diagnostic
performance of serum myoglobin, CK-MB and cTnI con-
centration obtained before and 60 min after initiation of
thrombolytic therapy, in predicting myocardial IRA pa-
tency, the most important aspect of early AMI care (36). To
Figure 2. Probability of IRA patency according to the myoglobin 60-min ratio. The probability of patency corresponds to the myoglobin
60-min ratio values greater than or equal to the specific cutpoints.
Table 3. Performance Characteristics of Serum Markers
Serum Marker
All Patients
ROC
Area
Diagnostic
Cut-point
Sensitivity for
Occlusion (%)
Specificity for
Occlusion (%)
Probability of Patency
(> Cut-point)
Probability of Occlusion
(< Cut-point)
Myo 60-min ratio 0.71 4.0 74 64 90 37
CK-MB 60-min ratio 0.70 3.3 70 63 88 35
cTnI 60-min ratio 0.71 2.0 69 60 87 33
Time Since Pain <6 h
Myo 60-min ratio 0.71 4.0 69 68 89 36
CK-MB 60-min ratio 0.70 3.3 62 68 87 34
cTnI 60-min ratio 0.71 2.0 68 62 88 31
CK-MB 5 creatine-kinase-MB; cTnI 5 cardiac Troponin-I; Myo 5 myoglobulin; ROC 5 receiver-operating characteristics.
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our knowledge, the current study is the largest study to date
to address this important clinical problem.
Diagnostic performance of serum markers. The 60-min
myoglobin ratio of $4.0 yielded 90% probability of a patent
IRA (Fig. 2, and Tables 3 and 4), suggesting that emer-
gency coronary angiography to determine their IRA status
may be unnecessary when this pattern of release of myoglo-
bin is observed. In our series, 229 (55%) patients had
60-min myoglobin ratios $4.0, indicating that a strategy
utilizing myoglobin marker would have allowed noninvasive
determination of IRA patency in a significant number of
patients. However, the probability of a patent IRA was still
substantial even with 60-min myoglobin ratios of ,4.0
(Tables 3 and 4). Moreover, the combined use of the
60-min ratios of all three markers did not result in a
significant improvement of the predictive value for occlu-
sion. The use of serum markers in combination with other
noninvasive markers of IRA patency, including resolution of
ST segment elevation and chest pain (8), may improve the
specificity for detection of IRA occlusion. If confirmed
through appropriate studies, such improved predictive ac-
curacy may allow rapid triage of patients to rescue angio-
plasty, when the clinical and laboratory findings are consis-
tent with IRA occlusion.
The diagnostic performance of myoglobin, CK-MB and
cTnI in the current study is similar to that found in our
previous pilot study (12). The performance of the single
60-min serum marker value was unsatisfactory for all three
markers. It is probable that the single time point, 60-min
serum marker measurement correlated not only with the
IRA patency status, but also with the extent of initial
myocardial injury. An extensive AMI may have yielded a
60-min myoglobin ratio $4.0 in the absence of IRA
patency. Conversely, a small AMI may have resulted in a
lower 60-min serum marker value, despite IRA patency.
The usefulness of serum myoglobin for noninvasive
prediction of infarct artery patency, either alone or in
combination with other cardiac marker proteins, has been
demonstrated by our group (12) and by other investigators
(14–16,18,24,25,37,38). Ellis et al. (15) reported that in 42
patient receiving thrombolytic therapy, the myoglobin 60-
min ratio cutoff of 4.6 conferred 100% sensitivity and 85%
specificity for the detection of occlusion. Similarly, Apple et
al. (23) found that in 25 consecutive patients given throm-
bolysis for AMI, the myoglobin 90-min cutoff of 5.0
conferred 100% sensitivity and 76.5% specificity for detec-
tion of occlusion. In comparison, in the present study the
myoglobin 60-min ratio at the cutoff of 4.0 yielded sensi-
tivity and specificity for occlusion of 74% and 64%, respec-
tively. The higher sensitivity and specificity of the 60-min
myoglobin ratio observed in the studies by Ellis et al. (15)
and Apple et al. (23) may be due to their small sample size.
Despite a considerable body of literature showing its
utility for noninvasive assessment of reperfusion, the mea-
surement of serum myoglobin for this purpose has not
become widely adopted into clinical care, possibly because
the previous studies included a modest number of patients
and concerns were raised about myoglobin’s nonspecificity
for cardiac muscle (39). However, our findings indicate that
nonspecific elevation of myoglobin is infrequent in patients
with AMI and ST segment elevations who are selected to
receive thrombolytic therapy. The short turnaround time of
approximately 30 min (measured from test ordering until
availability of result) for urgent myoglobin determinations
performed in the central laboratory, and possibly even less
when performed in the emergency department, would
enhance myoglobin’s utility in noninvasive assessment of
IRA patency status.
Apple et al. (23) have found in a series of 25 patients that
early serial measurements of cTnI were a more accurate
predictor of early IRA patency status 90 min after throm-
bolytic therapy than were CK-MB or myoglobin. The
performance of the 60-min cTnI ratio in our series was no
better than that of the 60-min myoglobin or CK-MB mass
ratios. Although the molecular mass of cTnI (23.5 kDa)
subunit is close to that of myoglobin (17.8 kDa), its initial
rate of increase might be slightly slower due to its predom-
inantly (97%) myofibrillar distribution (40). In addition,
because all cTnI results below the lower detection limit of
the assay were collectively expressed as 0.4 ng/ml, it is
possible that this may have resulted in an underestimation of
the cTnI 60-min ratio, and that higher ratios may have been
observed using an assay capable of measuring cTnI values
between 0.0 and 0.39 ng/ml.
Limitations of the study. There are limits to the conclu-
sions that we can draw from the present study. It has been
previously shown that combined analysis of noninvasive
markers (i.e., CK peak and resolution of ST segment
elevation) (13), continuous ST segment monitoring (41)
and the combination of resolution of ischemic discomfort,
reperfusion arrhythmias and normalization of electrocardio-
gram (7) can improve evaluation of infarct-related artery
patency. The other clinical data noted earlier in the article
were not available in the TIMI 10B trial, but studies in
progress at our institution are evaluating the contribution of
the biochemical markers, when used in combination with
clinical and ECG markers of IRA patency.
The performance of the cardiac markers in the current
study should be interpreted in the context of the overall
patency rate (78%) achieved at 60 min by the thrombolytic
Table 4. Diagnostic Performance of the 60-min
Myoglobin Ratio
Myoglobin
60-min Ratio
<4.0 >4.0
Probability of patency 63% 90%
Probability of occlusion 37% 10%
Number of patients 190 (45%) 229 (55%)
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agents used in the TIMI 10B study. The efficacy of cardiac
markers in detecting IRA patency may vary depending on
the type of the agent and adjunctive therapy used.
Conclusions. Our findings indicate that early identifica-
tion of patients with patent IRA after thrombolysis is
possible with biochemical markers. The diagnostic perfor-
mance of serum myoglobin, CK-MB and cTnI 60-min
ratios was similar. The probability of a patent IRA was the
highest (90%) in patients with 60-min myoglobin ratio
$4.0, and early invasive interventions such as rescue angio-
plasty may not be necessary in this group. Thus, serum
marker determinations at baseline and 60 min after throm-
bolysis may permit rapid triage of patients receiving throm-
bolytic therapy by ruling out IRA occlusion.
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